75000 - Document - Document and Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
75010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS
link:presentationLink
link:calculationLink
link:definitionLink
75020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) 2
link:presentationLink
link:calculationLink
link:definitionLink
75050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
995455 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS
link:presentationLink
link:calculationLink
link:definitionLink
995465 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RECENT ACCOUNTING PRONOUNCEMENTS
link:presentationLink
link:calculationLink
link:definitionLink
995475 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS
link:presentationLink
link:calculationLink
link:definitionLink
995485 - Disclosure - GAIN FROM SALE OF PRIORITY REVIEW VOUCHER
link:presentationLink
link:calculationLink
link:definitionLink
995495 - Disclosure - FAIR VALUE MEASUREMENTS
link:presentationLink
link:calculationLink
link:definitionLink
995505 - Disclosure - FINANCIAL INSTRUMENTS
link:presentationLink
link:calculationLink
link:definitionLink
995515 - Disclosure - PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUES
link:presentationLink
link:calculationLink
link:definitionLink
995525 - Disclosure - INVENTORY
link:presentationLink
link:calculationLink
link:definitionLink
995535 - Disclosure - OTHER ASSETS
link:presentationLink
link:calculationLink
link:definitionLink
995545 - Disclosure - ACCRUED EXPENSES
link:presentationLink
link:calculationLink
link:definitionLink
995555 - Disclosure - STOCK-BASED COMPENSATION
link:presentationLink
link:calculationLink
link:definitionLink
995565 - Disclosure - OTHER (EXPENSE), INCOME NET
link:presentationLink
link:calculationLink
link:definitionLink
995575 - Disclosure - INCOME TAXES
link:presentationLink
link:calculationLink
link:definitionLink
995585 - Disclosure - REVOLVING CREDIT FACILITY
link:presentationLink
link:calculationLink
link:definitionLink
995595 - Disclosure - LEASES
link:presentationLink
link:calculationLink
link:definitionLink
995605 - Disclosure - (LOSS) EARNINGS PER SHARE
link:presentationLink
link:calculationLink
link:definitionLink
995615 - Disclosure - SEGMENT INFORMATION
link:presentationLink
link:calculationLink
link:definitionLink
995625 - Disclosure - COMMITMENTS AND CONTINGENCIES
link:presentationLink
link:calculationLink
link:definitionLink
995635 - Disclosure - SUBSEQUENT EVENTS
link:presentationLink
link:calculationLink
link:definitionLink
995645 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
995655 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995665 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995675 - Disclosure - FINANCIAL INSTRUMENTS (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995685 - Disclosure - PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUES (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995695 - Disclosure - INVENTORY (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995705 - Disclosure - OTHER ASSETS (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995715 - Disclosure - ACCRUED EXPENSES (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995725 - Disclosure - STOCK-BASED COMPENSATION (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995735 - Disclosure - OTHER (EXPENSE), INCOME NET (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995745 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995755 - Disclosure - SEGMENT INFORMATION (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995765 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995775 - Disclosure - Organization and Nature of Business - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995785 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RECENT ACCOUNTING PRONOUNCEMENTS - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995795 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995805 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS - Summary of Activity Related to Supply Agreement (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995815 - Disclosure - Gain from Sale of Priority Review Voucher - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995825 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured and Carried at Fair Value (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995835 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Fair Value of Level 3 Financial Liabilities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995845 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of carrying value and fair value of the Company's convertible notes (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995855 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995865 - Disclosure - FINANCIAL INSTRUMENTS - Summary of Company Financial Assets with Maturities of Less Than 90 Days Included in Cash Equivalents (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995875 - Disclosure - FINANCIAL INSTRUMENTS - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995885 - Disclosure - FINANCIAL INSTRUMENTS - Summary of Company Cash, Cash Equivalents and Short-term Investments (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995895 - Disclosure - Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995905 - Disclosure - Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summary of Product Revenues (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995915 - Disclosure - Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summarizes the concentration of the three largest customers (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995925 - Disclosure - Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summary of Change in Reserves for Discounts and Allowances (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995935 - Disclosure - Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summary of Total Reserves Included in Consolidated Balance Sheets (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995945 - Disclosure - Inventory - Summary of Components of Inventory (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995955 - Disclosure - Inventory - Summarizes The Balance Sheet Classification (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995965 - Disclosure - Inventory (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995975 - Disclosure - Other Assets - Summary of Other Current Assets (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995985 - Disclosure - Other Assets - Summary of Other Non-current Assets (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995995 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996005 - Disclosure - Indebtedness - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996015 - Disclosure - Indebtedness - Summary of Debt Facilities (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996025 - Disclosure - Indebtedness - Summarizes Total Gross Payments Due under Company's Debt Arrangements (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996035 - Disclosure - Stock Based Compensation - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996045 - Disclosure - Stock Based Compensation - Summary of Stock Awards Granted (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996055 - Disclosure - Stock Based Compensation - Summary of Stock Awards Granted (Parenthetical) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996065 - Disclosure - Stock Based Compensation - Summary of Stock-Based Compensation Expense by Grant Type and by Function Included within Consolidated Statements of Comprehensive Income (Loss) (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996065 - Disclosure - Stock Based Compensation - Summary of Stock-Based Compensation Expense by Grant Type and by Function Included within Consolidated Statements of Comprehensive Income (Loss) (Detail) [Default]
link:presentationLink
link:calculationLink
link:definitionLink
996075 - Disclosure - OTHER (EXPENSE), INCOME NET - Summary of Other Loss (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996085 - Disclosure - OTHER (EXPENSE), INCOME NET - (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996095 - Disclosure - Leases (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996105 - Disclosure - Income Taxes (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996115 - Disclosure - REVOLVING CREDIT FACILITY (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996125 - Disclosure - (LOSS) EARNINGS PER SHARE - Basic and Diluted Net Loss Per Share (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996135 - Disclosure - EARNINGS (LOSS) PER SHARE - SummarY of Potential Shares of Common Stock from the Computation of Diluted Earnings per Share (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996145 - Disclosure - EARNINGS (LOSS) PER SHARE - SummarY of Potential Shares of Common Stock from the Computation of Diluted Earnings per Share (Parenthetical) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996155 - Disclosure - SEGMENT INFORMATION - Company`S Segment, Including Segment Expenses, and A Reconciliation to Net Income (Loss) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996165 - Disclosure - SEGMENT INFORMATION (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996175 - Disclosure - Commitments and Contingencies - Summary of Aggregate Non-Cancelable Contractual Obligations Arising from Manufacturing Obligations (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996185 - Disclosure - Commitments and Contingencies (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996195 - Disclosure - EQUITY (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996205 - Disclosure - SUBSEQUENT EVENTS (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
Line of Credit Facility [Line Items]
Cumulative Effect of Accounting Change [Member]
Cumulative Effect, Period of Adoption, Adjustment [Member]
Type of Revenue [Extensible List]
Revenue, Product and Service [Extensible Enumeration]
Acquisition of strategic investments
Acquisition of strategic investments
Acquisition of strategic investments
Cash cash equivalents and investments amortized cost basis.
Cash Cash Equivalents And Investments Amortized Cost Basis
Cash, cash equivalents and investments, Amortized cost
Cash, cash equivalents and investments, Amortized cost
Summary of Accrued Expenses
Schedule of Accrued Liabilities [Table Text Block]
Preferred Stock, Shares Issued, Total
Preferred stock, shares issued
Preferred Stock, Shares Issued
Debt Disclosure [Text Block]
REVOLVING CREDIT FACILITY
Operating Lease, Liability
Operating Lease, Liability, Total
Operating lease liability
Interest expense
Interest Expense, Operating and Nonoperating
Interest Expense, Total
Interest expense
Change in fair value of derivatives
Purchase of Stock, Price Per Share
Purchase of Stock, Price Per Share
Common stock average price per share
Line of Credit
Long-Term Line of Credit
Long-Term Line of Credit, Total
Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest
Unrealized gains (loss) on investments, net of tax
Incremental compensation cost
Share-Based Payment Arrangement, Plan Modification, Incremental Cost
2026
Long-Term Debt, Maturity, Year Three
Debt Instrument, Federal Fund Rate
Secured Overnight Financing Rate
Debt Instrument, Basis Spread on Variable Rate
Commitments and Contingencies
Commitments and contingencies (Note 16)
Weighted Average Number of Shares Outstanding, Diluted
Diluted
Weighted-average common shares outstanding, diluted
Stock repurchased during period, shares
Stock Repurchased During Period, Shares
Segment Expenses and Other Segment Items
Segment Expenses and Other Segment Items
Segment expenses and other segment items
Deferred revenue, net of current portion
Contract with Customer, Liability, Noncurrent
Supply agreement.
Supply Agreement [Member]
Supply Agreement [Member]
Initial lease term of contract
Lessee, Operating Lease, Term of Contract
Schedule Of Inventory Table Text Block
Schedule Of Inventory Table Text Block
Schedule of components of inventory
Minimum [Member]
Minimum [Member]
2025
Long-Term Debt, Maturity, Year Two
Federal Fund Rate [Member]
Federal Fund Rate [Member]
Federal Fund Rate [Member]
Preferred Stock, Shares Outstanding, Ending Balance
Preferred Stock, Shares Outstanding, Beginning Balance
Preferred stock, shares outstanding
Preferred Stock, Shares Outstanding
Inventory [Axis]
FAIR VALUE MEASUREMENTS
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage
Stock options vesting right
Roche Collaboration Reimbursement
Roche Collaboration Reimbursement
Roche Collaboration Reimbursement
Common Stock, Shares, Issued, Total
Common stock, issued
Common Stock, Shares, Issued
Segment Reporting [Line Items]
Business Combination, Contingent Consideration, Liability, Total
Contingent consideration
Contingent consideration
Business Combination, Contingent Consideration, Liability
Principal amount
Total payments
Debt instrument, face amount
Debt Instrument, Face Amount
Income Tax Expense (Benefit), Total
Income Tax Expense (Benefit)
Provision for Income tax
Income tax expense
Income tax expense (benefit)
Deferred Revenue [Domain]
Payment for option exercise
Payment For Option Exercise
Payment for option exercise.
Debt Instrument, Periodic Payment, Principal
Counterparty Name
Counterparty Name [Domain]
Deferred Revenue Arrangement Type [Axis]
Restricted Stock Units [Member]
Restricted Stock Units (RSUs) [Member]
Cash and Money Market Funds [Member]
Cash Deposits And Money Market Funds [Member]
Cash deposits and money market funds.
Repayments of borrowings under the Revolving Credit Facility
Repayments of Lines of Credit
Repayments of borrowings under the Revolving Credit Facility
Line of Credit Facility, Maximum Borrowing Capacity
Line of Credit
Income Tax Authority, Name [Axis]
Cash, cash equivalents and restricted cash:
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation [Abstract]
Contingent consideration liabilities derecognized in connection with adoption of ASU 2025-07
Contingent Consideration Liabilities Derecognized
Contingent Consideration Liabilities Derecognized
Available for sale debt securities, Amortized cost
Debt Securities, Available-for-Sale, Amortized Cost
Available for sale debt securities, Amortized cost
Subsequent Event Type [Domain]
Other Accruals [Member]
Receivable Type [Axis]
Inventory [Domain]
Cost of Product and Service Sold
Cost of Goods and Services Sold, Total
Cost of sales
Liabilities, Fair Value Adjustment
Change in estimated fair value
Change in the fair value of contingent consideration
Change in the fair value of contingent consideration
Cash cash equivalents restricted cash and investments
Cash Cash Equivalents Restricted Cash And Investments
Cash cash equivalents restricted cash and investments.
Accrued clinical and pre-clinical costs
Accrued Clinical And Preclinical Costs Current
Accrued clinical and preclinical costs current.
Nonoperating Income (Expense)
Total other (expense) income, net
Debt Instrument [Table]
Schedule of Long-Term Debt Instruments [Table]
Chargebacks [Member]
Chargebacks [Member]
Chargebacks.
Income Statement [Abstract]
Accretion of investment discount, net
Accretion of investment discount, net
Amortization Of Discounts Premiums Investments Cash Equivalent And Short Term Investment
Amortization of discounts premiums investments cash equivalent and short term investment.
Deferred Tax Asset Net, Non Current
Deferred Tax Asset Net, Non Current
Deferred tax asset
Two Thousand Twenty Four Notes [Member]
Two Thousand Twenty Four Notes [Member]
2024 Notes
Debt Instrument, Unamortized Discount, Total
Unamortized discount
Debt Instrument, Unamortized Discount
Stock options granted to CEO
Grants, Stock options
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
March Two Thousand Twenty Four Performance Stock Units Plan [Member]
March Two Thousand Twenty Four Performance Stock Units Plan [Member]
March 2024 PSUs [Member]
Vesting [Axis]
Rebates [Member]
Rebates [Member]
Rebates.
Earnings Per Share, Basic
Earnings Per Share, Basic, Total
Earnings (loss) per common share, basic
Basic
(Loss) earnings per common share, basic
Summary of Change in Reserves for Discounts and Allowances
Summary Of Change In Reserves For Discounts And Allowances Table [Text Block]
Summary of change in reserves for discounts and allowances.
Document Period End Date
Document Period End Date
ACCRUED EXPENSES
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
Licensing and Collaboration Agreement [Member]
Licensing and collaboration agreement.
Licensing And Collaboration Agreement [Member]
Principal Transaction Revenue [Table]
Accounts receivable payment term
Accounts Receivable Payment Term
Accounts receivable payment term.
Finite-Lived Intangible Assets, Net, Ending Balance
Finite-Lived Intangible Assets, Net, Beginning Balance
Finite-Lived Intangible Assets, Net, Total
Intangible assets, net
Intangible Asset, Finite-Lived, after Accumulated Amortization
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period
Equal installments
Convertible Debt, The Term Loan, The Revolver and The Mortgage Loans [Member]
Convertible Debt And Term Loan And Revolver And Mortgage Loans [Member]
Convertible debt and term loan and revolver and mortgage loans.
Payments to Acquire Property, Plant, and Equipment, Total
Purchase of property and equipment
Payments to Acquire Property, Plant, and Equipment
Debt Instrument [Line Items]
Debt Instrument [Line Items]
Rest Of World [Member]
Rest of World [Member]
Rest of World [Member]
Common Stock, Shares Authorized
Common stock, shares
Statement of Stockholders' Equity [Abstract]
ASU 2020-06
Accounting Standard Update Two Thousand And Sixteen To Two Thousand And Eighteen [Member]
Accounting standard update two thousand and sixteen to two thousand and eighteen.
Commitments And Contingencies [Line Items]
Commitments And Contingencies [Line Items]
Commitments and contingencies.
Customer Two [Member]
Customer Two [Member]
Customer two.
Two Thousand Seventeen Capped Calls Partial Settlement [Member]
Two Thousand Seventeen Capped Calls Partial Settlement [Member]
2017 Capped Calls Partial Settlement [Member]
Investments
Investments [Domain]
Other Comprehensive Income (Loss), Net of Tax
Total other comprehensive (loss) income
BioMarin Pharmaceutical, Inc. [Member]
Bio Marin Pharmaceutical Incorporation [Member]
Bio Marin Pharmaceutical Incorporation.
Equity Incentive Plans [Member]
Equity Incentive Plans [Member]
Equity Incentive Plans [Member]
Eliminated accrued interest
Deposit Liabilities, Accrued Interest
Collaboration Receivable
Collaboration Receivable
Collaboration Receivable.
Debt instrument, interest rate per annum
Debt Instrument, Interest Rate, Stated Percentage
Cash and cash equivalents, Gross unrealized gains
Cash And Cash Equivalents Gross Unrealized Gain Before Tax
Cash and cash equivalents gross unrealized gain before tax.
Total cost and expenses
Costs and Expenses
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Total assets
Assets
Area of lease
Area of Land
Title of 12(b) Security
Title of 12(b) Security
Preferred Stock, Value, Issued, Ending Balance
Preferred Stock, Value, Issued, Beginning Balance
Preferred Stock, Value, Issued, Total
Preferred stock, $0.0001 par value, 3,333,333 shares authorized; none issued and outstanding
Preferred Stock, Value, Issued
Cash and Cash Equivalents [Member]
Cash and Cash Equivalents [Member]
Exercise of options for common stock
Stock Issued During Period, Value, Stock Options Exercised
Summary of Stock-Based Compensation Expense by Function Included within Condensed Consolidated Statements of Operations and Comprehensive Loss
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Title and Position [Domain]
Customer Concentration Risk [Member]
Customer Concentration Risk [Member]
Antidilutive Securities, Name [Domain]
Receivables, Net, Current [Abstract]
Conversion of shares excluded from computation of diluted EPS
Conversion of shares excluded from computation of diluted EPS
Conversion of shares excluded from computation of diluted EPS
Variable Rate [Axis]
Contractual Obligation, to be Paid, Year One
2027
Cash paid during the period for interest
Interest Paid, Excluding Capitalized Interest, Operating Activity
Other Nonoperating Income and Expense [Text Block]
OTHER EXPENSE, NET
Summary of Product Revenues
Disaggregation of Revenue [Table Text Block]
Debt Instrument, Periodic Payment, Total
Debt Instrument, Periodic Payment
Payment for full settlement of the principal value and accrued interest
Customer Four [Member]
Customer Four [Member]
Customer Four [Member]
Prepaid commercial expenses
Prepaid Commercial
Prepaid commercial.
Summary Of Inventory Balance Sheet Classification
SummaryOfInventoryBalanceSheetClassificationTableTextBlock
SummaryOfInventoryBalanceSheetClassificationTableTextBlock
Salary and Wage, Excluding Cost of Good and Service Sold
Salary and Wage, Excluding Cost of Good and Service Sold, Total
Annual base salary
Cash
Cash
LEASES
Lessee, Operating Leases [Text Block]
Purchase of available-for-sale securities
Payments to Acquire Debt Securities, Available-for-Sale
Total stockholders’ equity
Balance
Balance
Equity, Attributable to Parent
Accrued Litigation Settlement
Accrued Litigation Settlement
Accrued litigation contingency charge
Entity Address, Address Line Two
Entity Address, Address Line Two
Total other non-current assets
Other non-current assets
Other Assets, Noncurrent
Collaborative Arrangement and Arrangement Other than Collaborative
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Accrued contract manufacturing costs
Accrued Contract Manufacturing Expense Current
Accrued contract manufacturing expense current.
2024 Repurchase Program [Member]
Two Thousand And Twenty Four Repurchase Program [Member]
Two Thousand And Twenty Four Repurchase Program.
Income Tax Disclosure [Text Block]
INCOME TAXES
2027
Long Term Debt Maturities Repayments Of Principal After Year Four
Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date.
Income Tax Jurisdiction, Domestic State and Local [Member]
State [Member]
Earnings Per Share [Text Block]
(LOSS) EARNINGS PER SHARE
Partial settlement of capped call share options for 2024 Notes
Partial settlement of capped call share options for 2024 Notes
Partial settlement of capped call share options for 2024 Notes
Partial settlement of capped call
2019 Term Loan [Member]
Two Thousand And Nineteen Term Loan [Member]
Two Thousand And Nineteen Term Loan Member
Nationwide License Agreement [Member]
Nationwide License Agreement [Member]
Nationwide license agreement.
2022 Capped Call Transactions [Member]
2022 Capped Call Transactions [Member]
Number of Reportable Segments
Number of reportable segments
Cash, cash equivalents and investments, Fair value
Cash Cash Equivalents And Investments
Cash cash equivalents and investments.
Cash, Cash Equivalents And Investments
Cash, cash equivalents and investments, Fair value
Sales Revenue Net [Member]
Revenue Benchmark [Member]
Basis of Presentation
Basis of Accounting, Policy [Policy Text Block]
Segment Reporting, Reconciliation of Other Item by Segment to Consolidated [Table Text Block]
Schedule of Company`S Segment, Including Segment Expenses, and A Reconciliation to Net Income (Loss)
Effective Income Tax Rate Reconciliation, Tax Credit, Percent
Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total
Effective income tax rate
Effective income tax rate
Long-Term Debt
Aggregate long-term debt
Carrying value of debt facilities
Total carrying value of debt instruments
Credit Facility [Axis]
Effective Income Tax Rate Reconciliation [Table]
Stock, Class of Stock [Table]
Reconciliation of cash, cash equivalents and restricted cash:
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]
Available for sale debt securities, Gross unrealized losses
Available for sale debt securities, Gross unrealized gains
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Total manufacturing commitments
Contractual Obligation
Common Stock Covering Resulting Upon The Vesting Of Future Restricted Stock
Common Stock Covering Resulting Upon The Vesting Of Future Restricted Stock
Revolving Credit Facility [Member]
Revolving Credit Facility [Member]
Performance Share Units [Member]
Performance Share Units [Member]
Performance Share Units
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares
Vesting, Stock options
Proceeds from exercise of stock options and purchase of stock under the Employee Stock Purchase Program
Proceeds from Stock Options Exercised
Ryan Brown [Member]
Ryan Brown [Member]
Ryan Brown
Payments to Acquire Intangible Assets
Purchase of intangible assets
Purchase of intangible assets
Geographical
Geographical [Domain]
Debt Securities, Trading, Unrealized Loss
Loss of the change in fair value of this strategic investment
Statistical Measurement
Statistical Measurement [Axis]
Money Market Funds [Member]
Money Market Funds [Member]
Entity Interactive Data Current
Entity Interactive Data Current
Gain (Loss) on Extinguishment of Debt, Total
Gain (Loss) on Extinguishment of Debt
Loss on debt extinguishment
Loss on debt extinguishment
(Loss) gain on strategic investments
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Prompt Pay [Member]
Prompt Pay [Member]
Prompt pay.
Share-Based Payment Arrangement, Cost by Plan [Table Text Block]
Summary of Stock-Based Compensation Expense by Grant Type and by Function Included within Consolidated Statements of Comprehensive Income (Loss)
Gain From Sale Of Intangible Asset [Line Items]
Gain From Sale Of Intangible Asset [Line Items]
Gain from sale of intangible asset.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common Stock, Value, Issued, Ending Balance
Common Stock, Value, Issued, Beginning Balance
Common Stock, Value, Issued, Total
Common Stock, Value, Issued
Common stock, $0.0001 par value, 198,000,000 shares authorized; 106,279,142 and 105,623,500 issued and outstanding, respectively, at June 30, 2026 and 105,615,096 and 104,964,220 issued and outstanding, respectively, at December 31, 2025
Basic and Diluted Net Loss Per Share
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Inventory [Line Items]
Government and Government Agency Bonds [Member]
US Government Agencies Debt Securities [Member]
Collateralized Letter of Credit Cash Deposit
Collateralized Letter of Credit Cash Deposit
Collateralized Letter of Credit Cash Deposit
Cash and cash equivalents, Gross unrealized losses
Cash And Cash Equivalents Gross Unrealized Loss Before Tax
Cash and cash equivalents gross unrealized loss before tax.
Total liabilities
Liabilities
Collaborative Arrangement
Collaborative Arrangement [Member]
Other Noncash Income (Expense), Total
Other
Other Noncash Income (Expense)
Other
Deferred tax asset valuation allowance
Deferred Tax Assets, Valuation Allowance
Interest on Convertible Debt, Net of Tax
Add: interest expense, net of tax, on the Company's convertible debt
Add: interest expense, net of tax, on the Company's convertible debt
Payments/credits
Payments Credits Reserves For Discounts And Allowances
Payments credits reserves for discounts and allowances.
Product and Service [Axis]
Short-term Investments [Member]
Short-Term Investments [Member]
Retained Earnings (Accumulated Deficit), Beginning Balance
Retained Earnings (Accumulated Deficit), Total
Retained Earnings (Accumulated Deficit), Ending Balance
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Level 3 [Member]
Fair Value, Inputs, Level 3 [Member]
Non-current investments [Member]
Non-current investments [Member]
Non Current Investments [Member]
Non Cash Inventory Write Downs For Obsolescence
Non Cash Inventory Write Downs For Obsolescence
Non-cash inventory write-downs for obsolescence
Debt conversion costs for 2024 Notes
Debt conversion costs for 2024 Notes
Debt Conversion Costs
Debt Conversion Costs
Debt conversion costs for 2024 Notes
Increase (Decrease) in Accounts Payable
Increase (Decrease) in Accounts Payable, Total
Decrease in accounts payable
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments
Aggregate grant date fair value of equity
Revenues:
Revenues [Abstract]
Vesting [Domain]
Weighted average maturity period of available-for-sale securities
Weighted Average Maturity Period Of Available For Sale Securities
Weighted average maturity period of available for sale securities.
ORGANIZATION AND NATURE OF BUSINESS
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Stock Issued During Period, Shares, New Issues
Common stock issued
Other
Other Assets, Miscellaneous, Current
Customers Exceed [Member]
Customers Exceed [Member]
Customers Exceed [Member]
Schedule Of Certain Activity Related To Revenue With Supply Agreement [Table Text Block]
Schedule of certain activity related to revenue with supply agreement.
Schedule of Certain Activity Related to Revenue with Supply Agreement
Convertible Debt Securities [Member]
Convertible Debt [Member]
Underwritten offering.
Underwritten Offering [Member]
Underwritten Offering [Member]
Other Non-Current Assets Amortized Cost
Other Non-Current Assets Amortized Cost
Other non-current assets Amortized cost
Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer
Collaboration and other
Collaboration and other
Variable Rate [Domain]
Accounts Notes And Loans Receivable [Line Items]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Stock Repurchased During Period, Value
Share repurchases value
Certificates of Deposit [Member]
Certificates of Deposit [Member]
Restricted Cash
Restricted Cash, Total
Restricted cash
ASU 2020-06
Accounting Standards Update 2020-06 [Member]
Other Reconciling Items
Other Reconciling Items
Adjustments and reconciling items
Significant Accounting Policies
Significant Accounting Policies [Policy Text Block]
Significant Accounting Policies [Policy Text Block]
Subsequent Events [Text Block]
SUBSEQUENT EVENTS
Columbus Ohio [Member]
Columbus Ohio
Fair Value Hierarchy and NAV [Axis]
Level 2 [Member]
Officer Annual Targeting Bonus Percentage
Officer Annual Targeting Bonus Percentage
Officer annual targeting bonus percentage
F D A
F D A [Member]
FDA Member.
Summary of Total Reserves Included in Consolidated Balance Sheets
Summary Of Reserves For Discounts And Allowances Included In Consolidated Balance Sheets Table [Text Block]
Summary of reserves for discounts and allowances included in consolidated balance sheets.
Product Information [Line Items]
PMO Products [Member]
PMO Products [Member]
PMO Products [Member]
Inventory, Current [Table]
Debt Securities, Available-for-sale, Total
Available for sale debt securities, Fair value
Debt Securities, Available-for-Sale
Research and Development Expense (Excluding Acquired in Process Cost), Total
Research and development
Research and Development Expense (Excluding Acquired in Process Cost)
Base Rate [Member]
Base Rate [Member]
No Individual [Member]
No Individual [Member]
No Individual [Member]
Operating Lease, Liability, Current
Current portion of lease liabilities
Customer One [Member]
Customer One [Member]
Customer one.
Contingent research milestone payments
Milestone Payment To Be Paid By Company Upon Specified Research Milestone Achievement
Milestone payment to be paid by company upon specified research milestone achievement.
Concentration Risk Type
Concentration Risk Type [Domain]
Customer [Domain]
Total liabilities and stockholders’ equity
Liabilities and Equity
Other
Other Assets, Miscellaneous, Noncurrent
Research and Development Expense, Total
Research and development expense
Research and Development Expense
Reduction in the carrying amounts of the right of use assets
Reduction In The Carrying Amounts Of The Right Of Use Assets
Reduction in the carrying amounts of the right of use assets.
P R V [Member]
PRV
P R V
Lessee, Lease, Description [Table]
Document Fiscal Period Focus
Document Fiscal Period Focus
Prepaid Expense and Other Assets, Current [Abstract]
Other non-current assets
Non-current inventory
Inventory, Noncurrent
Inventory, Noncurrent, Total
Schedule of Inventory, Current [Table Text Block]
Summary of Components of Inventory
Title and Position [Axis]
Accrued royalties
Accrued Royalties, Current
Cash and cash equivalents, Amortized cost
Cash And Cash Equivalents Amortized Cost Basis
Cash and cash equivalents amortized cost basis.
Cash and cash equivalents, Amortized cost
Loss Contingency Accrual, Payments
Loss Contingency Accrual Payments
Accrued litigation settlement
Performance Shares [Member]
Performance Shares
Provision
Provision For Reserves For Discounts And Allowances
Provision for reserves for discounts and allowances.
Changes in operating assets and liabilities, net:
Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]
Cost and expenses:
Costs and Expenses [Abstract]
2024 Notes [Member]
2024 Notes [Member]
2024 Notes
Summary Of Significant Accounting Policies [Table]
Summary Of Significant Accounting Policies [Table]
Summary Of Significant Accounting Policies [Table]
Accrued income taxes
Accrued Income Taxes
Accrued Income Taxes, Total
Sale of Stock [Axis]
Development Milestone and Upfront Fee Recognized as Research and Development Expense
Development Milestone And Settlement Upfront Fee Recognized As Research And Development Expense
Development milestone and settlement upfront fee recognized as research and development expense.
Compensation and other personnel expenses
Compensation and Other Personnel Expenses
Compensation and Other Personnel Expenses
Summary of carrying value and fair value of the Company's convertible notes [Table Text Block]
Summary of carrying value and fair value of the Company's convertible notes[Text Block]
Summary of Carrying Value and Fair Value of the Company's Convertible Notes
License Agreement Fee
License Agreement Fee
License agreement fee
Decrease in cash, cash equivalents and restricted cash
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Entity Current Reporting Status
Entity Current Reporting Status
Estimates and Uncertainties
Use of Estimates, Policy [Policy Text Block]
Deferred revenue
Deferred Revenue
Deferred Revenue, Total
Level 1 [Member]
Fair Value, Inputs, Level 1 [Member]
Accounts Payable, Current
Accounts Payable, Current, Total
Accounts payable
Lysogene S,A.
Lysogene S A [Member]
Lysogene S.A. [Member]
Investment Type
Investment Type [Axis]
Financial Instrument
Financial Instrument [Axis]
Assets, Fair Value Disclosure, Total
Total assets
Assets, Fair Value Disclosure
Fair value, as of March 31, 2024
Fair value, as of December 31, 2023
Stock-based compensation expenses
Allocated Share Based Compensation Expenses
Amount of expenses for award under share-based payment arrangement. Excludes amount capitalized.
Document Transition Report
Document Transition Report
Up front payment for license and collaboration agreement
Up Front Payment for License and Collaboration Agreement
Up Front Payment for License and Collaboration Agreement
Commitments and Contingencies Disclosure [Abstract]
Value Added Tax Receivable
Tax-related receivables and prepaids
Upfront Fee To Be Paid On Certain Enrollment Achievement
Upfront Fee To Be Paid On Certain Enrollment Achievement
Upfront Fee To Be Paid On Certain Enrollment Achievement
Subsequent Event [Line Items]
Two Thousand Thirty Notes [Member]
2030 Notes
Two Thousand Thirty Notes [Member]
Two Thousand And Twenty Seven Senior Convertible Notes [Member]
Two Thousand And Twenty Seven Senior Convertible Notes [Member]
2027 Convertible Notes [Member]
Increase in inventory
Increase (Decrease) in Inventories, Total
Increase (Decrease) in Inventories
Increase in inventory
Accounting Standards Update
Accounting Standards Update [Domain]
Right of use assets and lease liability
Operating Lease, Right Of Use Assets And Lease Liability
Operating Lease, Right Of Use Assets And Lease Liability
Current liabilities:
Liabilities, Current [Abstract]
Reduction in carrying value of convertible notes
Reduction In Carrying Value Of Convertible Notes
Reduction In Carrying Value Of Convertible Notes
Share-Based Payment Arrangement [Abstract]
Common Stock [Member]
Common Stock [Member]
Finished goods
Inventory, Finished Goods, Net of Reserves
Accounting Standards Update
Accounting Standards Update [Axis]
Henogen SA [Member]
Henogen SA [Member]
Henogen SA.
Proceeds from Lines of Credit
Proceeds from Lines of Credit, Total
Proceeds from borrowings under the Revolving Credit Facility
Summary of Other Loss
Schedule of Other Nonoperating Income (Expense) [Table Text Block]
Credit Facility [Domain]
Statistical Measurement
Statistical Measurement [Domain]
Nonoperating Income (Expense) [Abstract]
Other (loss) income, net:
Michael A
Director [Member]
Stockholders’ equity:
Equity, Attributable to Parent [Abstract]
Weighted Average Number of Shares Outstanding, Basic, Total
Weighted Average Number of Shares Outstanding, Basic
Basic
Weighted-average common shares outstanding, basic
Arrowhead Pharmaceuticals Inc [Member]
Arrowhead Pharmaceuticals Inc [Member]
Arrowhead Pharmaceuticals Inc.
Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award
Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award
Assets
Assets [Abstract]
GAIN FROM SALE OF PRIORITY REVIEW VOUCHER
Gain Loss From Sale Of Intangible Assets Disclosure [Text Block]
Gain (loss) from sale of intangible assets.
Entity Central Index Key
Entity Central Index Key
Weighted Average Number of Shares Outstanding, Basic [Abstract]
Weighted average number of shares of common stock used in computing (loss) earnings per share:
Antidilutive Securities [Axis]
Line of Credit Facility [Table]
Class of Stock [Line Items]
Other Liabilities, Current, Total
Other current liabilities
Other Liabilities, Current
Nature of Operation, Product Information, Concentration of Risk [Table]
Current Fiscal Year End Date
Current Fiscal Year End Date
Second Arrowhead DM One Milestone [Member]
Second Arrowhead DM One Milestone [Member]
Second Arrowhead DM One Milestone [Member]
Increase (Decrease) in Accrued Liabilities
Increase (Decrease) in Accrued Liabilities, Total
(Decrease) increase in accrued expenses
Document Quarterly Report
Document Quarterly Report
Debt instrument, maturity date
Debt Instrument, Maturity Date
Net Income (Loss) Available to Common Stockholders, Diluted
Net Income (Loss) Available to Common Stockholders, Diluted, Total
Net (loss) income - diluted
Cost of sales (excluding amortization of in-licensed rights)
Cost Of Goods Sold Excluding Amortization
Cost of goods sold excluding amortization.
Compound annual growth rate of the Company's common stock exceeded that of the Nasdaq.
Compound annual growth rate
Schedule of product revenues concentration risk.
Schedule Of Product Revenues Concentration Risk [Table Text Block]
Schedule of Product revenue Concentration risks
Prepaid maintenance services
Prepaid Maintenance Services Current
Prepaid maintenance services, current.
2023 (April-December)
Long-Term Debt, Maturity, Remainder of Fiscal Year
Maturity Of Non Current Investments
Maturity of Non Current Investments
Maturity of Non Current Investments
Level 2 [Member]
Fair Value, Inputs, Level 2 [Member]
Schedule Of Cash And Cash Equivalents [Table]
Cash and Cash Equivalent [Table]
Net cash used in operating activities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Net cash used in operating activities
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Earnings Per Share, Diluted, Total
Increase in diluted earnings per share (in dollar per share)
Earnings Per Share, Diluted
Earnings (loss) per common share, diluted
Diluted
Preferred stock, par value
Preferred Stock, Par or Stated Value Per Share
Net (loss) income
Net (loss) income - basic
Reserves For Reduction To Accounts Receivable
Reserves for reduction to accounts receivable.
Reduction to accounts receivable, net
Manufacturing Costs
Manufacturing expenses
Increase (Decrease) in Other Operating Assets, Total
Increase (Decrease) in Other Operating Assets
Increase in other assets
(Increase) decrease in other assets
COMMITMENTS AND CONTINGENCIES
Commitments and Contingencies Disclosure [Text Block]
Gain From Sale Of Intangible Asset [Table]
Gain From Sale Of Intangible Asset [Table]
Gain from sale of intangible asset.
Restricted Stock Awards/Units (RSAs/RSUs) [Member]
Restricted Stock And Restricted Stock Units R S Us [Member]
Restricted stock and restricted stock units.
Total carrying value of debt facilities
Long-term debt
Loans Payable, Noncurrent
Total carrying value of debt instruments
Payment Terms
Accounts Receivable Payment Terms
Accounts Receivable Payment Terms
Summary of Other Non-current Assets
Schedule of Other Assets, Noncurrent [Table Text Block]
Contractual Obligation, to be Paid, Year Two
2028
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive (loss) income
Debt Instrument, Fair Value Disclosure
Fair value of debt facilities
Total fair value of debt instruments
Total fair value of debt instruments
Equity Components
Equity Components [Axis]
Cash flows from investing activities:
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]
Gain (Loss) on Investments
Gain (Loss) on Investments, Total
(Loss) gain on strategic investments
Loss on strategic investments
Loss (gain) on strategic investments
Deferred Compensation Plan Assets [Member]
Deferred Compensation Plan Assets [Member]
Deferred Compensation Plan Assets [Member]
LICENSE AND COLLABORATION AGREEMENTS
Collaborative Arrangement Disclosure [Text Block]
Statement of Cash Flows [Abstract]
Fair Value Hierarchy and NAV
Fair Value Hierarchy and NAV [Domain]
Summary of Company Cash, Cash Equivalents and Short-Term Investments
Cash, Cash Equivalent, and Investment [Table Text Block]
Income Tax Disclosure [Abstract]
Weighted Average Grant Date Fair Value, Stock options
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Strategic Equity Investments [Member]
Strategic Equity Investments Member
Strategic Investments [Member]
Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
Common stock issuable under the Company's convertible debt
Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities, Total
Common stock issuable under the Company's convertible debt
Contract Manufacturing Revenue [Member]
Contract Manufacturing Revenue [Member]
Contract Manufacturing Revenue [Member]
Assets and Liabilities Measured and Carried at Fair Value
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]
Principal Transaction Revenue [Line Items]
Depreciation, Depletion and Amortization, Total
Depreciation and amortization
Depreciation, Depletion and Amortization
Depreciation and amortization expense
FINANCIAL INSTRUMENTS
Issuance of common stock for exchange of 2024 Notes, shares
Issuance of common stock for exchange of 2024 Notes, shares
Issuance Of Common Stock For Conversion For Notes Shares
Issuance Of Common Stock For Conversion For Notes Shares
Letter of Credit Reduce
Letter of Credit Reduce
Letter of Credit Reduce
Line of Credit Facility, Increase, Accrued Interest
Chief Executive Officer
Chief Executive Officer [Member]
Long-Term Investments, Total
Long-Term Investments
Non-current investments
Preferred stock, shares authorized
Preferred Stock, Shares Authorized
Cash and Cash Equivalents [Line Items]
Cash and Cash Equivalents [Line Items]
Line of Credit Facility [Abstract]
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax
Unrealized (losses) gains on investments, net of tax
2024 Notes Induced Conversion [Member]
Two Thousand Twenty Four Notes Induced Conversion [Member]
Two Thousand Twenty Four Notes Induced Conversion [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Total number of potentially issuable common stock
Total number of potentially issuable common stock
Counterparty Name
Counterparty Name [Axis]
Accrued milestone costs
Accrued milestone costs
Accrued milestone costs
Cash cash equivalents and investments gross unrealized gain before tax.
Cash Cash Equivalents And Investments Gross Unrealized Gain Before Tax
Cash, cash equivalents and investments, Gross unrealized gains
Cash, cash equivalents and investments, Gross unrealized gains
Number of operating segments
Number of Operating Segments
Up-front and milestone expenses
Up-Front and Milestone Expenses
Up-Front and Milestone Expenses
Debt Securities, Available-for-sale, Current, Total
Available for sale debt securities current, Fair value
Debt Securities, Available-for-Sale, Current
Consulting Fee
Consulting Fee
Consulting fee
Increase (Decrease) in Deferred Revenue
Net decrease in deferred revenue
Decrease in deferred revenue
Royalty Damages
Royalty Damages
Royalty Damages
Receivable
Receivable [Domain]
Inventory
Total inventory
Inventory
Inventory, Net
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Other comprehensive (loss) income:
Non-US [Member]
Non-US
Rest Of World [Member]
Concentration Risk Benchmark [Domain]
Interest receivable
Interest Receivable
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
(Decrease) increase in lease liabilities and other liabilities
Noncash interest expense.
Noncash Interest Expense
Non-cash interest expense
Other Research and Development Expense
Research and development- other (excluding non-cash items)
Total accrued expenses
Accrued expenses
Accrued Liabilities, Current
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Long-Term Debt, Current Maturities, Total
Long-Term Debt, Current Maturities
Current portion of long-term debt
Carrying value of debt facilities, current
Customer [Axis]
Work in progress
Inventory, Work in Process, Gross
Available for sale debt securities, Gross unrealized losses
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Summary of Fair Value of Level 3 Financial Assets
Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]
Intangible Asset, Goodwill and Other [Abstract]
Document Type
Document Type
Cash flows from operating activities:
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]
Liabilities and Equity [Abstract]
Liabilities and Stockholders’ Equity
Cumulative Effect, Period of Adoption
Cumulative Effect, Period of Adoption [Domain]
Lessee, Lease, Description [Line Items]
Subsequent Event
Subsequent Event [Member]
Operating Income (Loss)
Operating income (loss)
Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]
Summary of Potential Shares of Common Stock from the Computation of Diluted Earnings per Share
Sale of Stock, Price Per Share
Common stock average price per share
Segment Reporting [Table]
2024 Convertible Notes [Member]
Two Thousand And Twenty Four Senior Convertible Notes [Member]
Two thousand and twenty four senior convertible notes.
Entity File Number
Entity File Number
Corporate Bonds [Member]
Corporate Bonds [Member]
Corporate Bonds
Undiscounted rent payment
Payments for Rent
Federal [Member]
Income Tax Jurisdiction, Domestic Federal [Member]
Bilal Arif [Member]
Bilal Arif [Member]
Bilal Arif
Location, Statement of Income, Balance [Axis]
Share Based Compensation Arrangement By Share Based Payment Awards Aggregate Fair Value
Share Based Compensation Arrangement By Share Based Payment Awards Aggregate Fair Value
Aggregate grant date fair value of equity
Accumulated Deficit [Member]
Retained Earnings [Member]
Debt Instrument, Term
Amortized Term
Interest Payable, Current
Accrued interest expense
Entity Registrant Name
Entity Registrant Name
Accounting Policies [Abstract]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net income (loss)
Selling, General and Administrative Expense, Total
Selling, general and administrative
Selling, General and Administrative Expense
Selling, general and administrative- other (excluding non-cash items)
Leases, term of contract extend
Lessee, Operating Lease, Renewal Term
Other Operating Segment [Member]
Operating Segments [Member]
Total Collaboration Agreement Fee
Total Collaboration Agreement Fee
Total Collaboration Agreement Fee
Entity Address, Address Line One
Entity Address, Address Line One
Prepaid regulatory
Prepaid Regulatory
Prepaid Regulatory
UNITED STATES
United States [Member]
United States [Member]
Raw materials
Inventory, Raw Materials, Net of Reserves
Annual Installment Fee
Annual Installment Fee
Annual Installment Fee
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Exercise of options for common stock, shares
Capitalized stock-based compensation and depreciation as inventory
Capitalized stock-based compensation and depreciation as inventory
Capitalized stock-based compensation and depreciation as inventory
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Average closing price
Total current assets
Assets, Current
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Fair Value, Recurring and Nonrecurring [Table]
Segments [Axis]
Income Tax Authority, Name [Domain]
Supplemental disclosure of cash flow information:
Supplemental Cash Flow Information [Abstract]
Gain (Loss) from Litigation Settlement
Gain (Loss) from Litigation Settlement, Total
Litigation settlement expense
Summary of Components of Accounts Receivable
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]
Royalty Revenue
Royalty Revenue
Royalty Revenue
Entity Small Business
Entity Small Business
Lacerta Therapeutics Inc [Member]
Lacerta Therapeutics Inc [Member]
Lacerta Therapeutics, Inc.
Roche Collaboration Agreement [Member]
Roche Collaboration Agreement [Member]
Roche Collaboration Agreement [Member]
Accrued Clinical Collaboration Costs
Accrued Clinical Collaboration Costs
Accrued clinical collaboration costs
Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements
Common stock issuable under the Company's equity incentive plans
Common stock issuable under the Company's equity incentive plans
Cumulative Effect of Accounting Change to Adopt ASU 2025-07
Cumulative Effect of Accounting Change to Adopt ASU 2025-07
Cumulative effect of accounting change to adopt ASU 2025-07
Proceeds from Sale and Maturity of Debt Securities, Available-for-sale, Total
Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale
Maturity and sales of available-for-sale securities
Long-Term Debt, Type [Axis]
Significant Accounting Policies [Text Block]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RECENT ACCOUNTING PRONOUNCEMENTS
Total accounts receivable, net
Accounts Receivable, after Allowance for Credit Loss, Current
Accounts receivable, net
Employee-related Liabilities, Current, Total
Accrued employee compensation costs
Employee-related Liabilities, Current
Schedule of Long-Term Debt Instruments [Table Text Block]
Summary of Carrying Value and Fair Value of the Company's Convertible Notes
Summary of Debt Facilities
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Commitments And Contingencies [Table]
Commitments And Contingencies [Table]
Commitments and Contingencies [Table]
Earnings Per Share [Abstract]
Effective Income Tax Rate Reconciliation [Line Items]
Plan Name [Axis]
Subsequent Event Type [Axis]
Equity [Abstract]
Product and Service [Domain]
Two Thousand Twenty Four Notes Repurchase [Member]
Two Thousand Twenty Four Notes Repurchase [Member]
2024 Notes Repurchase [Member]
Total reserves
Beginning balance
Ending balance
Accounts Receivable, Allowance for Credit Loss, Current
Cash flows from financing activities:
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]
Strategic investments noncurrent.
Strategic Investments Noncurrent
Strategic investments
Loss Contingency Damages Awarded Value
Loss Contingency, Damages Awarded, Value
Summary of Fair Value of Level 3 Financial Liabilities
Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]
Entity Tax Identification Number
Entity Tax Identification Number
Treasury Stock, Common, Shares
Treasury Stock, shares
Treasury Stock Common Shares
Treasury Stock, shares
September Twenty Two Thousand Twenty Five [Member]
September Twenty Two Thousand Twenty Five [Member]
September 20, 2025 [Member]
Accounts Receivable [Member]
Accounts Receivable [Member]
Increase Decrease In Manufacturing-Related Deposits And Prepaids
Increase Decrease In Manufacturing-Related Deposits And Prepaids
Decrease in manufacturing-related deposits and prepaids
Net (increase) decrease in manufacturing-related deposits and prepaids
Prepaid Expense and Other Assets, Noncurrent [Abstract]
Equity Component
Equity Component [Domain]
NationWide Children Hospital [Member]
Nationwide Children Hospital [Member]
Nationwide Children Hospital.
Common Stock Covering Under Plan
Common Stock Covering Under Plan
Issuance of common stock for exchange of 2024 Notes, shares
Issuance of common stock for exchange of notes shares
Issuance of common stock for exchange of notes shares
Entity Address, City or Town
Entity Address, City or Town
Manufacturing related deposits and prepaids
Manufacturing related deposits and prepaids
Manufacturing-related deposits and prepaids
Business Acquisition
Business Combination [Axis]
2024
Long-Term Debt, Maturity, Year One
Income Taxes Paid, Net, Total
Income Tax Paid, after Refund Received
Cash paid during the period for income taxes
Restricted Cash, Noncurrent
Restricted cash in other assets
Restricted cash
Restricted cash non-current
Segments [Domain]
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Investment in license agreement
Equity Method Investments
Concentration Risk Type
Concentration Risk Type [Axis]
Inventory Write-down
Inventory write-downs
Commercial Paper [Member]
Commercial Paper [Member]
Up-front Payment Arrangement [Member]
Up-front Payment Arrangement [Member]
Employee Stock Purchase Plan [Member]
Employee Stock Purchase Plan [Member]
Employee stock purchase plan.
Antidilutive Security, Excluded EPS Calculation [Table]
Deferred revenue, current portion
Contract with Customer, Liability, Current
Proceeds from sale of rare pediatric disease priority review voucher, Net of commission
Proceeds From Sale Of Rare Pediatric Disease Priority Review Voucher Net Of Commission
Proceeds from sale of rare pediatric disease priority review voucher, Net of commission.
Statement [Table]
Statement [Table]
Deferred Revenue, Current, Total
Deferred Revenue, Current
Deferred Revenue, Current
Other segment items
Other Segment Items
Other Segment Items
Stock-based compensation expense
Share-Based Payment Arrangement, Expense
Stock-based compensation expense
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
(Loss) income before income tax expense
(Loss) income before income tax expense (benefit)
Repurchases Of Common Stock
Repurchases Of Common Stock
Repurchases of common stock
Entity Shell Company
Entity Shell Company
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Net cash provided by investing activities
Other Income and Expenses [Abstract]
Restricted Stock Units Vested
Restricted Stock Units Vested
Vest of restricted stock units
Statement [Line Items]
Statement [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Vesting Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Maximum [Member]
Maximum [Member]
Consulting Agreement [Member]
Consulting Agreement [Member]
Consulting Agreement [Member]
Debt Disclosure [Abstract]
Sale of Stock [Domain]
Interest income
Investment Income, Interest
Allocated to the equity investment
Equity Method Investment, Amount Sold
Equity Method Investment, Amount Sold, Total
Business Acquisition, Acquiree
Business Combination [Domain]
Debt convertible senior notes percentage
Debt Convertible Senior Percentage
Debt Convertible Senior Percentage
Litigation Settlement, Fee Expense
Litigation contingency charge
Product revenue related reserves
Accrued Product Revenue Related Reserve Current
Accrued product revenue related reserve current.
Repurchases Of Common Stock Shares
Repurchases Of Common Stock Shares
Repurchases Of Common Stock Shares
Concentration Risk Benchmark [Axis]
Total [Member]
Total
Total [Member]
Debt Instrument, Redemption, Period [Domain]
Subsequent Events [Abstract]
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Segment Reporting, Reconciliation of Profit (Loss) by Segment to Consolidated [Abstract]
Reconciliation of profit or loss
Share repurchase program, excise taxes and other fees
Share Repurchase Program, Excise Taxes And Other Fees
Share Repurchase Program, Excise Taxes And Other Fees
Weighted Average Grant Date Fair Value, Restricted stock units
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Earnings Per Share, Basic [Abstract]
(Loss) earnings per share:
Investments
Investments
Investments, Total
Amortization of Debt Issuance Costs
Amortization of Debt Issuance Costs
Bank Time Deposits [Member]
Collaboration and other receivables
Collaboration and other receivable current
Collaboration and other receivable current
Two Thousand Seventeen Capped Call Transactions [Member]
Two Thousand Seventeen Capped Call Transactions [Member]
2017 Capped Call Transactions [Member]
Current assets:
Assets, Current [Abstract]
Debt Issuance Costs, Net, Total
Unamortized discount - debt issuance costs
Debt Issuance Costs, Net
Liabilities, Fair Value Disclosure, Total
Fair value at the beginning of the period
Total liabilities
Liabilities, Fair Value Disclosure
Fair value, as of March 31, 2024
Fair value, as of December 31, 2023
Accrued professional fees
Accrued Professional Fees, Current
Leases [Abstract]
Other Accruals [Member]
Other Accruals [Member]
Other accruals.
Document Fiscal Year Focus
Document Fiscal Year Focus
Accumulated Other Comprehensive (Loss) Income [Member]
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]
Intangible assets and property and equipment included in accounts payable and accrued expenses
Noncash or Part Noncash Acquisition, Fixed Assets Acquired
Common Stock, Shares, Outstanding, Ending Balance
Common Stock, Shares, Outstanding, Beginning Balance
Common stock, outstanding
Common Stock, Shares, Outstanding
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Accretion of Investment Discount, Net
Accretion of Investment Discount, Net
Accretion of investment discount, net
Line of Credit Facility, Periodic Payment, Interest
Line of Credit, Interest Payment
ELEVIDYS [Member]
ELEVIDYS [Member]
ELEVIDYS [Member]
Financial Instruments
Financial Instruments [Domain]
Prepaid maintenance services
Prepaid maintenance services noncurrent
Prepaid maintenance services noncurrent
Net Income (Loss) Attributable to Parent, Diluted, Total
Net Income (Loss) Attributable to Parent, Diluted
Net income (loss) - diluted
Milestone Payment Received
Milestone Payment Received
Milestone payment received
Equity investment agreement.
Equity Investment Agreement [Member]
Equity Investment Agreement [Member]
SOFR [Member]
Secured Overnight Financing Rate (SOFR) [Member]
Lease liabilities, net of current portion
Operating Lease, Liability, Noncurrent
Term of Installment Fee
Term of Installment Fee
Term of installment fee
Cash, cash equivalents and investments, Gross unrealized losses
Cash Cash Equivalents And Investments Gross Unrealized Loss Before Tax
Cash cash equivalents and investments gross unrealized loss before tax.
Cash, cash equivalents and investments, Gross unrealized losses
Tenant improvement allowance
Payments for (Proceeds from) Tenant Allowance
Treasury Stock [Member]
Treasury Stock, Preferred [Member]
Treasury stock, at cost, 655,642 and 650,876 shares at March 31, 2026 and December 31, 2025, respectively
Treasury Stock, Value
Treasury stock, at cost, 655,642 and 650,876 shares at March 31, 2026 and December 31, 2025, respectively
Treasury stock, at cost, 655,642 and 650,876 shares at June 30, 2026 and December 31, 2025, respectively
Other
Other Accrued Liabilities, Current
Additional Paid in Capital, Common Stock, Ending Balance
Additional Paid in Capital, Common Stock, Beginning Balance
Additional paid-in capital
Additional Paid in Capital, Common Stock
Security Exchange Name
Security Exchange Name
Stock-based compensation
APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition
Other, net
Other Nonrecurring (Income) Expense, Total
Other Nonrecurring (Income) Expense
Other, net
Revenues
Total revenues
Revenues
Total revenues
Warrants with an exercise price
Class of Warrant or Right, Exercise Price of Warrants or Rights
Entity Address, State or Province
Entity Address, State or Province
Adjustments To Product Revenue Reserves Relating To Sales In Prior Years
Adjustments To Product Revenue Reserves Relating To Sales In Prior Years
Adjustments relating to prior periods
Right of use assets
Operating Lease, Right-of-Use Asset
Amendment Flag
Amendment Flag
Customer Three [Member]
Customer Three [Member]
Customer three.
Lease liabilities arising from obtaining right of use assets
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
STOCK-BASED COMPENSATION
Share-Based Payment Arrangement [Text Block]
Concentration of credit risk percentage
Concentration Risk, Percentage
Interest Expense, Debt, Total
Interest expense reduced
Interest Expense, Debt
Interest expense debt
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Debt Instrument
Debt Instrument [Axis]
Other, net
Other Nonoperating Income (Expense)
Other income, net
Other (expense) income, net
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Total cash, cash equivalents and restricted cash
End of period
Beginning of period
Total inventory
Inventory Current and Noncurrent Net
Inventory current and noncurrent net.
Two Thousand Twenty Seven Notes [Member]
Two Thousand Twenty Seven Notes [Member]
2027 Notes
Revolving Credit Facility Upfront Fee
Revolving Credit Facility Upfront Fee
Revolving credit facility upfront fee
Corporate Bond [Member]
Corporate Bond Securities [Member]
City Area Code
City Area Code
Issuance of common stock under employee stock purchase plan
Stock Issued During Period, Value, Employee Stock Purchase Plan
Roche Holding A.G. [Member]
Roche [Member]
Roche.
Share based compensation expense included in costs and expenses.
Share Based Compensation Expense Included In Costs And Expenses
Total stock-based compensation expense included in expenses
Contractual Obligation, to be Paid, Remainder of Fiscal Year
2026 (July-December)
Accounts receivable and reserves for product sales.
Accounts Receivable And Reserves For Product Sales [Text Block]
PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUES
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule Of Accounts Notes Loans And Financing Receivable [Table]
Accounts and Financing Receivables [Table]
INVENTORY
Inventory Disclosure [Text Block]
Debt Instrument, Redemption, Period [Axis]
Common stock, par value
Common Stock, Par or Stated Value Per Share
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents [Abstract]
Manufacturing-related deposits and prepaids
Manufacturing Related Deposits And Prepaid Expense Non Current
Manufacturing related deposits and prepaid expense non current.
Total current liabilities
Liabilities, Current
Summary of Aggregate Non-Cancelable Contractual Obligations Arising from Manufacturing Obligations
Contractual Obligation, Fiscal Year Maturity [Table Text Block]
Prepaid clinical and pre-clinical expenses
Prepaid Clinical And Preclinical Expenses Current
Prepaid clinical and preclinical expenses current.
Manufacturing Commitments Agreement [Member]
Manufacturing Commitments Agreement [Member]
Manufacturing commitments agreement Member
SEGMENT INFORMATION
Segment Reporting [Text Block]
Collaborative Arrangement and Arrangement Other than Collaborative
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Long-Term Debt, Maturity, Year Four
2026
Catalent and Thermo [Member]
Catalent And Thermo [Member]
Catalent and Thermo Member
Trading Symbol
Trading Symbol
Product sales receivable, net of discounts and allowances
Billed Contracts Receivable
Operating Cycle
Inventory operating cycle
Geographical
Geographical [Axis]
Share-Based Payment Arrangement, Amount Capitalized
Capitalized stock-based compensation costs
Subsequent Event [Table]
Grants, Restricted stock units
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period
Expanded Grants, Stock options
Entity Emerging Growth Company
Entity Emerging Growth Company
Additional Paid-In Capital [Member]
Additional Paid-in Capital [Member]
Plan Name [Domain]
Other Liabilities, Noncurrent, Total
Other non-current liabilities
Other Liabilities, Noncurrent
Unvested Tranche Member
Share-Based Payment Arrangement, Tranche One [Member]
Summary Of Significant Accounting Policies [Line Items]
Summary Of Significant Accounting Policies [Line Items]
Summary Of Significant Accounting Policies [Line Items]
Prepaid Insurance
Prepaid insurance
Clinical trial expenses
Clinical Trial Expenses
Clinical Trial Expenses
Payments related to obtaining Revolving Credit Facility
Payments related to obtaining Revolving Credit Facility
Payments related to obtaining Revolving Credit Facility
Payments related to obtaining Revolving Credit Facility
Issuance of common stock under employee stock purchase plan, shares
Stock Issued During Period, Shares, Employee Stock Purchase Plans
Summary of Stock Awards Granted
Share-Based Payment Arrangement, Activity [Table Text Block]
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]
Supplemental schedule of non-cash activities:
Cover [Abstract]
Summary of Company Financial Assets with Maturities of Less Than 90 Days Included in Cash Equivalents
Schedule of Cash and Cash Equivalents [Table Text Block]
Dilutive Securities
Dilutive Securities, Shares
Dilutive Securities, Shares
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage
Restricted and Performance Stock Units Member
Restricted and Performance Stock Units [Member]
Restricted and Performance Stock Units [Member]
Facility- and technology-related expenses (excluding depreciation and amortization)
Facility and Technology Related Expenses
Facility and Technology Related Expenses
Issuance of common stock for exchange of 2024 Notes
Issuance of common stock for exchange of notes value
Issuance of common stock for exchange of notes value
Payments to Acquire Investments
Payments to Acquire Investments, Total
Purchase of investments
Long-Term Debt, Type [Domain]
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated other comprehensive income (loss), net of tax
Concentration of Credit Risk
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Summary of Other Current Assets
Schedule of Other Current Assets [Table Text Block]
Amortization of Intangible Assets, Total
Amortization of in-licensed rights
Intangible Asset, Finite-Lived, Amortization Expense
Share-based Payment Arrangement, Noncash Expense, Total
Stock-based compensation
Share-Based Payment Arrangement, Noncash Expense
Stock-based compensation expense
Share-Based Payment Arrangement, Expense, after Tax
Subtotal
Adjustments to reconcile net loss to cash flows from operating activities:
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]
Product Revenues [Member]
Revenue, Product and Service Benchmark [Member]
Short-term Investments, Total
Short-term investments
Short-Term Investments
Fair Value Disclosures [Abstract]
Cash and Cash Equivalents, at Carrying Value, Ending Balance
Cash and Cash Equivalents, at Carrying Value, Beginning Balance
Cash and Cash Equivalents, at Carrying Value, Total
Cash and cash equivalents
Cash and Cash Equivalent
Cash and cash equivalents, Fair value
Underwritten public offering.
Underwritten Public Offering [Member]
Underwritten Public Offering [Member]
Share Repurchase Program, Remaining Authorized, Amount
Share repurchase program, authorized, amount
Bedford Massachusetts [Member]
Bedford Massachusetts
Ending Balance
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount
Beginning Balance
Net cash provided by financing activities
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Up-front and collaboration license fees
Up-front and Collaboration License Fees
Up-front and Collaboration License Fees
Royalty Revenue [Member]
Royalty Revenue [Member]
Royalty Revenue [Member]
Payables and Accruals [Abstract]
Restricted Cash and Investments
Restricted Cash and Investments, Total
Restricted cash and investments
Cash Equivalents, at Carrying Value, Total
Cash equivalents
Cash Equivalents, at Carrying Value
Entity Filer Category
Entity Filer Category
Debt Instrument, Name
Debt Instrument, Name [Domain]
Component of accrued expenses
Reserves For Component Of Accrued Expenses
Reserves for component of accrued expenses.
Fair value convertible note exchange
Fair value convertible note exchange
Fair value convertible note exchange
Increase (Decrease) in Accounts Receivable
Net decrease (increase) in accounts receivable, net
Decrease (increase) in accounts receivable
Impairment of investment in private companies
Impairment of equity investment
Impairment of equity investment
Equity Method Investment, Other-than-Temporary Impairment
Property, Plant and Equipment, Net, Ending Balance
Property, Plant and Equipment, Net, Beginning Balance
Property, Plant and Equipment, Net, Total
Property and equipment, net
Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization
Product revenues, net
Revenue from Contract with Customer, Excluding Assessed Tax, Total
Products, net
Revenue from Contract with Customer, Excluding Assessed Tax
Cumulative Effect, Period of Adoption
Cumulative Effect, Period of Adoption [Axis]
Balance (in shares)
Balance (in shares)
Shares, Outstanding
Inventory Disclosure [Abstract]
OTHER ASSETS
Other Assets Disclosure [Text Block]
Segment Reporting [Abstract]
Total other current assets
Other current assets
Other Assets, Current
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Statement of Financial Position [Abstract]
Local Phone Number
Local Phone Number